Silodosin Capsule
NDC Package 33342-385-12
Package Information
Silodosin capsules is silodosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). This formulation utilizes a capsule delivery system. Marketed by Macleods Pharmaceuticals Limited, this product is identified by NDC 33342-385 and is authorized under FDA application ANDA211166.
Identification & Billing
- RxCUI: 809477 - silodosin 8 MG Oral Capsule
- RxCUI: 826612 - silodosin 4 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 33342 - Macleods Pharmaceuticals Limited
- 33342-385 - Silodosin
- 33342-385-12 - 100 BLISTER PACK in 1 CARTON / 10 CAPSULE in 1 BLISTER PACK
- 33342-385 - Silodosin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (33342-385). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 33342-385-12 identifies a specific commercial package of 100 blister pack in 1 carton / 10 capsule in 1 blister pack of Silodosin, a human prescription drug labeled by Macleods Pharmaceuticals Limited. This capsule is formulated for oral use and contains silodosin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Macleods Pharmaceuticals Limited on December 03, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Silodosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Silodosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.
How is this Macleods Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 33342038512. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.